Abstract
We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19.
Keywords: Immunogenicity; Neutralizing antibodies; SARS-COV-2; Vaccine; Virus-like-particles.
【저자키워드】 SARS-CoV-2, Vaccine, immunogenicity, Neutralizing antibodies, Virus-like-particles., 【초록키워드】 COVID-19, Coronavirus disease 2019, immunization, Spike protein, Formulation, Neutralizing activity, Antibody binding, clinical evaluation, mice, SARS-CoV-2 spike protein, vaccine candidate, adjuvant, IgG1, single dose, Coronavirus-2, aluminum, Syrian golden hamster, phosphate, Support, acute respiratory syndrome, Virus-like particle, isotype, effort, injection, SARS-CoV-2 S, prefusion, neutralization titer, IgG2, selected, identify, evaluated, form, expressing, 【제목키워드】 Immunity, Spike protein, virus-like particle vaccine, prefusion, elicit, expressing, the SARS-CoV-2,